PAR
Par Drugs And Chemicals Limited (PAR) Stock Analysis
Par Drugs and Chemicals Limited manufactures active pharmaceutical ingredients and intermediates for domestic and export markets. It supplies APIs used in antibiotics and specialty therapies. The company operates API plants with regulatory compliance focus. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹109.50
-6.46% 1W | +8.90% 52W
Market Cap
135 CR
P/E Ratio
10.3
52W High
₹180
52W Low
₹78
Div. Yield
0%
Beta
0.4
50 DMA
₹121.6
200 DMA
₹99.2
Profit Margin
13.3%
Inst. Own.
0%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 22.93 | 25.89 | 24.00 | 22.82 | 22.61 | 34.66 | 21.38 | 22.33 | 26.05 | 28.66 | 29.34 | 19.61 | 31.28 |
| Expenses | 18.79 | 18.53 | 18.77 | 16.72 | 18.37 | 23.25 | 19.95 | 19.90 | 22.49 | 22.60 | 23.29 | 18.17 | 24.91 |
| Operating Profit | 4.14 | 7.36 | 5.23 | 6.10 | 4.24 | 11.41 | 1.43 | 2.43 | 3.56 | 6.06 | 6.05 | 1.44 | 6.37 |
| OPM % | 18.05% | 28.43% | 21.79% | 26.73% | 18.75% | 32.92% | 6.69% | 10.88% | 13.67% | 21.14% | 20.62% | 7.34% | 20.36% |
| Other Income | 0.01 | 0.05 | 0.23 | -0.05 | 0.07 | 1.02 | 0.27 | 0.79 | 1.84 | 0.48 | 1.33 | 0.36 | 0.94 |
| Interest | 0.02 | 0.03 | 0.02 | 0.05 | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 | 0.05 | 0.01 | 0.04 | 0.02 |
| Depreciation | 0.83 | 0.85 | 0.87 | 0.89 | 0.90 | 0.91 | 0.91 | 0.92 | 0.90 | 0.94 | 0.93 | 0.93 | 0.96 |
| Profit before tax | 3.30 | 6.53 | 4.57 | 5.11 | 3.39 | 11.49 | 0.78 | 2.28 | 4.48 | 5.55 | 6.44 | 0.83 | 6.33 |
| Tax % | 25.15% | 25.27% | 25.16% | 27.20% | 25.07% | 25.15% | 24.36% | 27.63% | 25.67% | 25.59% | 25.47% | -3.61% | 25.59% |
| Net Profit | 2.47 | 4.89 | 3.42 | 3.72 | 2.53 | 8.60 | 0.58 | 1.65 | 3.33 | 4.13 | 4.80 | 0.85 | 4.71 |
| EPS in Rs | 2.01 | 3.97 | 2.78 | 3.02 | 2.06 | 6.99 | 0.47 | 1.34 | 2.71 | 3.36 | 3.90 | 0.69 | 3.83 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 33 | 33 | 49 | 42 | 46 | 56 | 61 | 75 | 96 | 96 | 101 | 104 | 109 |
| Expenses | 26 | 26 | 40 | 34 | 38 | 46 | 45 | 59 | 78 | 73 | 81 | 87 | 89 |
| Operating Profit | 7 | 7 | 8 | 8 | 8 | 9 | 16 | 16 | 18 | 23 | 20 | 17 | 20 |
| OPM % | 22% | 22% | 17% | 19% | 18% | 17% | 26% | 22% | 19% | 24% | 19% | 17% | 18% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 4 | 3 |
| Interest | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 |
| Profit before tax | 1 | 1 | 3 | 3 | 3 | 6 | 15 | 13 | 15 | 20 | 18 | 17 | 19 |
| Tax % | 27% | 58% | 42% | 42% | 24% | 21% | 21% | 27% | 25% | 26% | 26% | 24% | |
| Net Profit | 1 | 0 | 2 | 2 | 3 | 5 | 12 | 9 | 11 | 14 | 13 | 13 | 14 |
| EPS in Rs | 1.65 | 0.78 | 3.43 | 2.78 | 2.79 | 3.87 | 9.44 | 7.49 | 9.21 | 11.78 | 10.86 | 10.65 | 11.78 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 32% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 3.0% | 11.0% | 12.0% |
| Profit CAGR | -2.0% | 1.0% | 38.0% |
Shareholding Pattern
Promoters73.37%
Public26.63%
Promoters73.41%
Public26.59%
Promoters73.41%
Public26.59%
Promoters73.41%
DIIs0.09%
Public26.51%
Promoters73.41%
DIIs0.09%
Public26.51%
Promoters74.21%
Public25.79%
Promoters74.21%
FIIs0.07%
DIIs0.05%
Public25.68%
Promoters73.37%
Public26.63%
Promoters73.41%
Public26.59%
Promoters73.41%
DIIs0.09%
Public26.51%
PAR
Holdings Analysis
Key strengths & risk signals
52
Overall
58
Fundamental
46
Technical
Risks (4)
OVERVALUED! PEG of 10.30 means expensive relative to growth rate.
BEARISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 23,702 vs down days: 49,740. Ratio: 0.48x
RECOVERY MODE! Current price (109.5) above 200-day but below 50-day.
POSITIVE YEAR! Stock gained 8.9% in the last year.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (121.6) is above 200-day average (99.2) - positive signal.
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
APPROACHING OVERSOLD! RSI at 36.5 - watch for reversal.
Fundamental & Technical Analysis
52Overall
58Fundamental
46Technical
Fundamental Breakdown
Growth Quality
16/30
Revenue CAGR: 11.0% (GOOD, 11/15). Profit CAGR: 1.0% (SLOW, 5/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.3% profit margin - acceptable profitability.
PEG Valuation
0/10
OVERVALUED! PEG of 10.30 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
14/20
MODERATE PUBLIC HOLDING! 25.79% public ownership - balanced ownership structure.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (121.6) is above 200-day average (99.2) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (109.5) above 200-day but below 50-day.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
4/10
POSITIVE YEAR! Stock gained 8.9% in the last year.
Volume Sentiment
5/30
BEARISH SENTIMENT! In last 30 days: 9 up days, 21 down days. Avg volume on up days: 23,702 vs down days: 49,740. Ratio: 0.48x
RSI
4/5
APPROACHING OVERSOLD! RSI at 36.5 - watch for reversal.
52W Range
2/5
LOWER HALF! Trading at 30.9% of 52W range - weakness visible.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -6.5% (1 week), -13.9% (1 month), 4.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.40 - stable stock, less market risk.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PAR | ₹109.50 | 10.3 | 13.3% | 11.0% | 1.0% | +8.9% | 52 | BREAKDOWN | +42.7% | +423.3% | +20.3% | +59.6% |
| KREBSBIO | ₹60.20 | – | -55.9% | -23.1% | – | -13.9% | 51 | CONSOLIDATION | -52.8% | +8.7% | +27.3% | +2.9% |
| BALAXI | ₹22.10 | 49.1 | 0.9% | -7.1% | -68.6% | -46.1% | 48 | APPROACHING SUPPORT | +333.3% | +116.7% | +14.1% | +14.1% |
| BALPHARMA | ₹95.80 | 21.1 | 2.2% | 0.1% | 34.7% | +21.4% | 71 | CONSOLIDATION | +450.0% | -69.4% | +34.4% | +5.4% |
| ALPA | ₹53.50 | 31.8 | 3.8% | 4.3% | 6.1% | -34.9% | 47 | BREAKDOWN | -91.5% | -28.6% | +25.1% | -23.9% |
| NATCAPSUQ | ₹160.40 | – | -8.1% | 3.6% | – | -27.7% | 37 | BREAKDOWN | +1.8% | +14.0% | +7.7% | -16.8% |
| VAISHALI | ₹7.80 | – | 4.1% | 18.0% | -15.2% | -22.7% | 51 | BREAKDOWN | – | +278.0% | – | -15.0% |
| MEDICO | ₹22.00 | 13.2 | 5.8% | 13.8% | 21.9% | -54.4% | 58 | BOUNCE FROM SUPPORT | +38.9% | -57.6% | +81.2% | +22.2% |
Data from TradeAlone · Updated daily
No news tagged for PAR yet.
